# Safety and Efficacy of Transcatheter Edge-to-Edge Repair for Atrial Functional Mitral Regurgitation

Study · id `cardio:ct-nct07414225` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07414225](<https://clinicaltrials.gov/study/NCT07414225>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07414225

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems; Heart failure; Valve and congenital heart disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 400 participants.

## Technical summary

Registry record NCT07414225. Randomized; no masking; primary purpose treatment. Start 2026-06-01 (actual); primary completion 2030-02-25 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 400 participants (planned count; ClinicalTrials.gov record NCT07414225, source copy `cardio:ctgov-nct07414225-2026-09-11`, retrieved 2026-10-26)
- Started: 2026-06-01 (actual) (ClinicalTrials.gov record NCT07414225, source copy `cardio:ctgov-nct07414225-2026-09-11`, retrieved 2026-10-26)
- Primary completion: 2030-02-25 (anticipated) (ClinicalTrials.gov record NCT07414225, source copy `cardio:ctgov-nct07414225-2026-09-11`, retrieved 2026-10-26)
- Completion: 2030-02-25 (anticipated) (ClinicalTrials.gov record NCT07414225, source copy `cardio:ctgov-nct07414225-2026-09-11`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07414225, source copy `cardio:ctgov-nct07414225-2026-09-11`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07414225-2026-09-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety and Efficacy of Transcatheter Edge-to-Edge Repair for Atrial Functional Mitral Regurgitation
- Acronym: STAR
- Condition: Atrial Functional Mitral Regurgitation
- Intervention (Device): Transcatheter Edge-to-Edge Repair
- Intervention (Drug): Guideline-Directed Medical Therapy (GDMT) for cardiovascular disease
- Lead sponsor: Beijing Anzhen Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry condition terms include this condition: Mitral regurgitation (`cardio:mitral-regurgitation`)
- Registry lists this organization as the lead sponsor: Beijing Anzhen Hospital (`cardio:org-beijing-anzhen-hospital`)

## Provenance

Content hash: 181cef9fd64b9de93633a35be733be8b95ae059cf661f2d656e67ccde0aac80c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
